Alibaba Health Information Technology (0241) AI Stock Analysis

• Market Cap: $93.33B
• Dividend Yield: N/A
• Average Volume (3M): 86.17M
• Price to Earnings (P/E): 60.1
• Beta (1Y): 2.16
• Revenue Growth: 12.02%
• EPS Growth: 40.17%
• Country: HK
• Employees: 1,422
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 0.07
• Shares Outstanding: 16,124,672,000
• 10 Day Avg. Volume: 66,821,331
• 30 Day Avg. Volume: 86,174,668
• PEG Ratio: 1.17
• Price to Book (P/B): 4.33
• Price to Sales (P/S): 2.31
• P/FCF Ratio: 51.28
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 4.39
• Enterprise Value/Gross Profit: 18.09
• Enterprise Value/Ebitda: 90.51
• 1Y Price Target: $5.98
• Price Target Upside: 3.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 63 Neutral
• Price Target: HK$6.50 ▲(12.26% Upside)

Alibaba Health Information Technology's strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and financial stability. However, technical indicators suggest weak momentum, and the high P/E ratio indicates potential overvaluation, which tempers the overall score.

Alibaba Health Information Technology Business Overview & Revenue Model

Company Description

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. It offers range of prescription drugs, over-the-counter drugs, nutritional supplements, medical devices, contact lenses, and various other health-related products through its online stores on Tmall.com and offline pharmacy outlets to business-to-customer and business-to-business customers; and pharmaceutical products, medical devices and healthcare products, health food, sexual health and family planning products, contact lenses, and medical and healthcare services through its e-commerce platform. The company also provides medical and healthcare services, including medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and TCM through various channels, such as Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. In addition, it engages in the tracking business; provision of network hospital, healthcare related internet information, internet information, and healthcare related technical services; operation of internet hospitals; and asset management services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited is based in Causeway Bay, Hong Kong.

How the Company Makes Money

Alibaba Health generates revenue through multiple streams, primarily from its online healthcare services, which include e-pharmacy sales, telemedicine consultations, and health management services. The company earns money by taking a commission on healthcare transactions facilitated through its platform, as well as through subscription fees from healthcare providers utilizing its health information systems. Additionally, partnerships with hospitals and pharmaceutical companies help to expand its service offerings and reach, contributing to its earnings. The growing trend of digital health solutions, especially in response to the COVID-19 pandemic, has further bolstered its revenue potential as more consumers and healthcare providers adopt these technologies.

Alibaba Health Information Technology Financial Statement Overview

Summary

Alibaba Health Information Technology shows strong financial health with impressive revenue and profit growth, efficient cost management, and robust cash flow generation. The company's low leverage and strong equity position further enhance its financial stability.

Income Statement

Alibaba Health Information Technology has demonstrated strong revenue growth with a 7.95% increase in the latest year. The gross profit margin has improved to 24.29%, indicating effective cost management. Net profit margin also increased to 4.68%, reflecting enhanced profitability. The EBIT and EBITDA margins have shown positive trends, suggesting operational efficiency improvements.

Balance Sheet

The company maintains a very low debt-to-equity ratio of 0.0022, indicating minimal leverage and financial risk. Return on equity has improved to 8.78%, showcasing effective use of shareholder funds. The equity ratio stands at a healthy level, reflecting a strong capital structure.

Cash Flow

Free cash flow growth has surged by 90.49%, highlighting robust cash generation capabilities. The operating cash flow to net income ratio is 0.29, indicating solid cash flow relative to earnings. The free cash flow to net income ratio is nearly 1, demonstrating efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	15.30B	30.60B	27.03B	26.76B	20.58B	15.52B
Gross Profit	3.72B	7.43B	5.90B	5.70B	4.11B	3.62B
EBITDA	742.87M	1.62B	999.05M	-24.48M	-188.12M	52.14M
Net Income	716.21M	1.43B	883.48M	535.65M	-265.56M	348.59M
Balance Sheet
Total Assets	21.18B	21.18B	19.71B	20.75B	19.20B	17.74B
Cash, Cash Equivalents and Short-Term Investments	8.10B	8.10B	9.55B	10.92B	10.55B	11.64B
Total Debt	35.52M	35.52M	82.17M	77.80M	135.41M	37.74M
Total Liabilities	4.87B	4.87B	5.19B	5.60B	5.13B	3.46B
Stockholders Equity	16.31B	16.31B	14.54B	15.17B	14.10B	14.30B
Cash Flow
Free Cash Flow	697.52M	1.38B	1.06B	250.08M	409.43M	992.35M
Operating Cash Flow	697.52M	1.40B	1.08B	255.69M	424.36M	1.01B
Investing Cash Flow	-2.23B	-2.60B	-4.88B	-532.44M	1.87B	-4.96B
Financing Cash Flow	-53.17M	-72.52M	-1.98B	-111.28M	-58.63M	8.92B

Alibaba Health Information Technology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.79
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0241, the sentiment is Negative. The current price of 5.79 is below the 20-day moving average (MA) of 6.20, below the 50-day MA of 6.25, and above the 200-day MA of 5.07, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 39.21 is Neutral, neither overbought nor oversold. The STOCH value of 31.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0241.

Alibaba Health Information Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6618	―	HK$200.09B	38.69	8.52%	―	18.56%	79.54%
2696	―	HK$38.94B	43.75	27.37%	―	2.57%	18.79%
0241	―	$93.33B	60.12	9.31%	―	12.02%	40.17%
2367	―	HK$44.08B	17.52	29.64%	1.73%	36.70%	22.26%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1833	―	$35.10B	168.29	1.37%	37.89%	14.56%	―
1952	―	HK$17.27B	―	-15.75%	―	102.73%	38.42%

Alibaba Health Information Technology Corporate Events

Alibaba Health Grants 949,000 RSUs Under 2024 Scheme

Alibaba Health Information Technology Limited has announced the grant of 949,000 Restricted Share Units (RSUs) to 17 employees as part of its 2024 Share Award Scheme. This initiative is designed to incentivize employees and align their interests with the company’s long-term goals, potentially enhancing employee retention and motivation. The RSUs have varied vesting periods, primarily between two to four years, and are subject to specific terms and conditions set by the company.

The most recent analyst rating on (HK:0241) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Alibaba Health Information Technology stock, see the HK:0241 Stock Forecast page.

Alibaba Health Signs Lease for Pharmaceutical Logistics Expansion

Alibaba Health Information Technology Limited has entered into a lease agreement through its subsidiary, Alibaba Health Pharmaceutical Chain, with Hangzhou Chuanfu for a 30-month lease of a production plant and ancillary facilities in Hangzhou, China. This transaction, classified as a connected transaction under the Listing Rules, involves the use of the premises as a warehouse for pharmaceutical products and medical devices, with the total rent and property management fees capped at RMB34.8 million for the lease term. The agreement will impact the company’s financial statements by recognizing the right-of-use asset, reflecting its strategic expansion in pharmaceutical logistics.

The most recent analyst rating on (HK:0241) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Alibaba Health Information Technology stock, see the HK:0241 Stock Forecast page.

Alibaba Health Establishes Nomination Committee to Enhance Board Diversity

Alibaba Health Information Technology Limited has established a Nomination Committee to ensure effective governance and diversity within its board of directors. The committee will be composed mainly of independent non-executive directors and will focus on maintaining a diverse and skilled board to align with the company’s corporate strategy. This move is expected to enhance the company’s governance structure and support its strategic objectives by ensuring a balanced representation of skills and backgrounds on the board.

The most recent analyst rating on (HK:0241) stock is a Buy with a HK$4.20 price target. To see the full list of analyst forecasts on Alibaba Health Information Technology stock, see the HK:0241 Stock Forecast page.

Alibaba Health Passes All Resolutions at 2025 AGM

Alibaba Health Information Technology Limited announced the successful passage of all resolutions at its Annual General Meeting held on August 8, 2025. Key resolutions included the adoption of financial statements, re-election of directors, and authorization for share issuance and repurchase, reflecting strong shareholder support and strategic alignment with the company’s growth objectives.

The most recent analyst rating on (HK:0241) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Alibaba Health Information Technology stock, see the HK:0241 Stock Forecast page.